KYLE BLOOMFIELD: Open Payments
NPI 1003446667 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$845 in 42 payments from 9 companies in 2025. Trend: 2023 $773 · 2024 $646 · 2025 $845
Food & beverage: $845
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $240 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $231 |
| Janssen Biotech, Inc. | 5 | $118 |
| GENZYME CORPORATION | 5 | $103 |
| Phathom Pharmaceuticals, Inc. | 8 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Celltrion USA Inc. | 1 | $18 |
Products named: XIFAXAN, RINVOQ, DUPIXENT, TREMFYA, VOQUEZNA, LINZESS, RELISTOR, ENTYVIO.
Industry payments across KY — which companies pay providers there.
